- Home
- CHRS vs DHF Comparison
CHRS vs DHF Comparison
Compare CHRS & DHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- DHF
- Stock Information
- Founded
- CHRS 2010
- DHF 1998
- Country
- CHRS United States
- DHF United States
- Employees
- CHRS N/A
- DHF N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- DHF Finance Companies
- Sector
- CHRS Health Care
- DHF Finance
- Exchange
- CHRS Nasdaq
- DHF Nasdaq
- Market Cap
- CHRS 84.2M
- DHF 172.4M
- IPO Year
- CHRS 2014
- DHF N/A
- Fundamental
- Price
- CHRS $0.73
- DHF $2.59
- Analyst Decision
- CHRS Buy
- DHF
- Analyst Count
- CHRS 3
- DHF 0
- Target Price
- CHRS $4.68
- DHF N/A
- AVG Volume (30 Days)
- CHRS 1.3M
- DHF 451.1K
- Earning Date
- CHRS 08-07-2025
- DHF 01-01-0001
- Dividend Yield
- CHRS N/A
- DHF 7.65%
- EPS Growth
- CHRS N/A
- DHF N/A
- EPS
- CHRS N/A
- DHF N/A
- Revenue
- CHRS $272,251,000.00
- DHF N/A
- Revenue This Year
- CHRS N/A
- DHF N/A
- Revenue Next Year
- CHRS $106.56
- DHF N/A
- P/E Ratio
- CHRS N/A
- DHF N/A
- Revenue Growth
- CHRS 19.87
- DHF N/A
- 52 Week Low
- CHRS $0.66
- DHF $2.06
- 52 Week High
- CHRS $2.43
- DHF $2.39
- Technical
- Relative Strength Index (RSI)
- CHRS 41.45
- DHF 62.77
- Support Level
- CHRS $0.72
- DHF $2.50
- Resistance Level
- CHRS $0.77
- DHF $2.58
- Average True Range (ATR)
- CHRS 0.04
- DHF 0.02
- MACD
- CHRS 0.00
- DHF 0.00
- Stochastic Oscillator
- CHRS 13.65
- DHF 75.00
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. It invests predominantly in fixed-income securities of below-investment-grade credit quality.